gastric cancer

News

NICE’s track record in cancer drugs: the impact of the CDF and the role of interim funding

Amgen in $1.9bn swoop for Five Prime and its gastric cancer ...

Amgen is to buy US biotech Five Prime Therapeutics for around $1.9 billion, adding a potential gastric cancer drug to its pipeline.

News

Five Prime eyes financing after positive results with stomac...

Shares in US biotech Five Prime Therapeutics more than tripled after it reported promising trial results with stomach cancer drug candidate bemarituzumab, returning the stock to levels not

News

FDA fast-tracks Leap’s gastric cancer immunotherapy

Leap Therapeutics will get a swift FDA review for its lead drug DKN-01 for a form of gastric and gastroesophageal junction (G/GEJ) cancer after being awarded fast-track status by the regula

News

Pieris begins gastric cancer combination trial with Lilly's ...

US biotech Pieris Pharmaceuticals has begun a collaboration and supply agreement with Eli Lilly, trialling its cancer drug PRS-343 in combination with the big pharma’s Cyramza (ramucirumab)

News

AstraZeneca's (AZ) Tagrisso (osimertinib)

AstraZeneca to unveil key data for cancer drugs at ASCO

AstraZeneca plans to unveil data at this year’s American Society of Clinical Oncology (ASCO) conference that could expand the number of patients who could be treated with two of its most im

News

Merck's Keytruda fails in gastric cancer trial

Trial missed overall survival endpoint

Amgen in $1.9bn swoop for Five Prime and its gastric cancer ...

Five Prime eyes financing after positive results with stomac...

FDA fast-tracks Leap’s gastric cancer immunotherapy

Pieris begins gastric cancer combination trial with Lilly's ...

AstraZeneca to unveil key data for cancer drugs at ASCO

Merck's Keytruda fails in gastric cancer trial

Kyverna rises on stiff person syndrome data

How to meet your physicians where they are online

gastric cancer

Editor's Picks